Viracta Therapeutics IncNASDAQ:VIRX
- LAST PRICE1.4400
- TODAY'S CHANGE (%)-0.0500 (-3.3557%)
- Bid / Lots1.3600/ 1
- Ask / Lots1.8800/ 1
- Open / Previous Close1.5200 / 1.4900
- Day Range
- 52 Week Range
- Volume16,074
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VIRX |
|---|---|---|
| 09:32 ET | 157 | 1.52 |
| 09:34 ET | 100 | 1.51 |
| 09:36 ET | 200 | 1.51 |
| 12:03 ET | 1000 | 1.47 |
| 12:09 ET | 1200 | 1.44 |
| 12:34 ET | 100 | 1.4773 |
| 12:38 ET | 100 | 1.47 |
| 12:45 ET | 100 | 1.4773 |
| 12:52 ET | 100 | 1.4773 |
| 12:59 ET | 100 | 1.47 |
| 01:08 ET | 100 | 1.47 |
| 01:12 ET | 100 | 1.47 |
| 01:21 ET | 100 | 1.47 |
| 01:24 ET | 200 | 1.45 |
| 01:35 ET | 300 | 1.47 |
| 01:46 ET | 5400 | 1.44 |
| 01:50 ET | 100 | 1.45 |
| 02:02 ET | 100 | 1.4773 |
| 02:08 ET | 100 | 1.47 |
| 02:13 ET | 100 | 1.5 |
| 02:18 ET | 100 | 1.5 |
| 02:20 ET | 100 | 1.5037 |
| 02:27 ET | 100 | 1.51 |
| 02:31 ET | 100 | 1.5 |
| 02:33 ET | 100 | 1.49 |
| 02:38 ET | 100 | 1.49 |
| 02:51 ET | 100 | 1.5073 |
| 03:00 ET | 100 | 1.501 |
| 03:03 ET | 100 | 1.503 |
| 03:14 ET | 100 | 1.5073 |
| 03:18 ET | 100 | 1.5073 |
| 03:27 ET | 100 | 1.5 |
| 03:30 ET | 100 | 1.5 |
| 03:38 ET | 300 | 1.47 |
| 03:41 ET | 200 | 1.494 |
| 03:43 ET | 2028 | 1.46 |
| 03:52 ET | 400 | 1.44 |
| 03:59 ET | 603 | 1.44 |
Mar 13, 2023
BRIEF-Viracta Therapeutics Reports Q4 And Full Year 2022 Financial Results And Provides A Corporate Update, from 4:27PM ET on Monday Mar 13, 2023 by Thomson Reuters
4:27PM ET on Monday Mar 13, 2023 by Thomson ReutersViracta Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update, from 4:05PM ET on Monday Mar 13, 2023 by GlobeNewswire
4:05PM ET on Monday Mar 13, 2023 by GlobeNewswire
Mar 8, 2023
Viracta Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference, from 4:05PM ET on Wednesday Mar 08, 2023 by GlobeNewswire
4:05PM ET on Wednesday Mar 08, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Viracta Therapeutics Inc | 57.2M | -1.1x | --- |
AVROBIO Inc | 56.9M | -0.5x | --- |
Senti Biosciences Inc | 56.1M | -7.0x | --- |
Aptose Biosciences Inc | 56.1M | -0.9x | --- |
Passage Bio Inc | 59.0M | -0.4x | --- |
Praxis Precision Medicines Inc | 55.0M | -0.2x | --- |
Company Information
Viracta Therapeutics, Inc. is a clinical-stage, precision oncology company. The Company is focused on advancing new medicines for the treatment of virus-associated malignancies. The Company conducts clinical trials for its combination product candidate as a therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma. Its lead product candidate is an all-oral combination therapy of its investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including Phase II basket trial for the treatment of multiple subtypes of relapsed/refractory EBV+ lymphoma (NAVAL-1), as well as a Phase Ib/II trial for the treatment of EBV+ recurrent and other EBV+ solid tumors. The Company's product candidate pipeline also includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510, a preclinical-stage PDK-1 inhibitor.
Contact Information
- Headquarters
- 2533 S COAST HWY 101, SUITE 210CARDIFF BY THE SEA, CA, United States 92007
- Phone
- 858-400-8470
- Fax
- 650-266-3501
Executives
- Independent Chairman of the Board
- Roger Pomerantz
- President, Chief Executive Officer, Director
- Mark Rothera
- Chief Financial Officer, Chief Operating Officer, Secretary
- Daniel Chevallard
- Chief Medical Officer
- Lisa Rojkjaer
- Director
- Ivor Royston
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $57.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 38.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.22 |
EPS | $-1.30 |
Book Value | $1.59 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
